🎗️ Endometrial Cancer FIGO 2023 Stage (with molecular)
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
Clinical takeaway
FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009.
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Staging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
How it works
Non-aggressive (G1–2 endometrioid): IA no/< ½ MI, IB ≥ ½, IIA cervical stroma, IIB substantial LVSI. Aggressive: IC confined, IIC any MI. III/IV by anatomic extension. Molecular changes early confined disease only: POLEmut → IAmPOLEmut, p53abn + MI → IICmp53abn.
Key points
- FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009.
- POLEmut confined to the corpus is downstaged to IAmPOLEmut (excellent prognosis, supports de-escalation regardless of LVSI/grade).
- p53abn confined disease with any myometrial invasion is upstaged to IICmp53abn (poor prognosis, escalate adjuvant therapy).
- MMRd and NSMP are recorded as subscripts but do not change the stage; for stage III/IV molecular subtype is recorded only.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Histologic type | Non-aggressive (G1–2 endometrioid) |
|---|---|
| Anatomic extent | Confined to endometrium/polyp, no myometrial invasion |
| Molecular subtype | Unknown / not done |
→FIGO stageStage IA
- FIGO 2023 stage：Stage IA
- Management direction：Surgical staging (total hysterectomy + BSO ± sentinel/systematic nodes); adjuvant therapy by risk stratification (histology/grade/myometrial invasion/LVSI/molecular) deciding observation, vaginal brachytherapy, external-beam pelvic radiation or chemotherapy
- Notes：FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage
| Histologic type | Aggressive (G3, serous, clear-cell, carcinosarcoma, undifferentiated, etc.) |
|---|---|
| Anatomic extent | Distant metastasis (IVC) |
| Molecular subtype | NSMP |
→FIGO stageStage IVCmNSMP
- FIGO 2023 stage：Stage IVCmNSMP (MMRd/NSMP do not change the stage, recorded as a subscript only; for stage III/IV the molecular subtype is recorded only)
- Management direction：Surgery (aim for optimal cytoreduction) + platinum chemotherapy ± radiation; advanced/recurrent may add immunotherapy (dMMR/MMRd: dostarlimab/pembrolizumab; pMMR: combined with lenvatinib)
- Notes：FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage
Frequently asked questions
- What is Endometrial Cancer FIGO 2023 Stage (with molecular)?
- Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
- How is Endometrial Cancer FIGO 2023 Stage (with molecular) calculated? What is the core formula?
- Non-aggressive (G1–2 endometrioid): IA no/< ½ MI, IB ≥ ½, IIA cervical stroma, IIB substantial LVSI. Aggressive: IC confined, IIC any MI. III/IV by anatomic extension. Molecular changes early confined disease only: POLEmut → IAmPOLEmut, p53abn + MI → IICmp53abn.
- When is Endometrial Cancer FIGO 2023 Stage (with molecular) used?
- Staging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
- What are the key clinical points for Endometrial Cancer FIGO 2023 Stage (with molecular)?
- FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009. POLEmut confined to the corpus is downstaged to IAmPOLEmut (excellent prognosis, supports de-escalation regardless of LVSI/grade). p53abn confined disease with any myometrial invasion is upstaged to IICmp53abn (poor prognosis, escalate adjuvant therapy). MMRd and NSMP are recorded as subscripts but do not change the stage; for stage III/IV molecular subtype is recorded only.
- What are the limits and cautions when using Endometrial Cancer FIGO 2023 Stage (with molecular)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Endometrial Cancer FIGO 2023 Stage (with molecular) calculated in practice? Can you show a worked example?
- Inputs: Histologic type Non-aggressive (G1–2 endometrioid), Anatomic extent Confined to endometrium/polyp, no myometrial invasion, Molecular subtype Unknown / not done → Result: FIGO stage Stage IA（FIGO 2023 stage: Stage IA, Management direction: Surgical staging (total hysterectomy + BSO ± sentinel/systematic nodes); adjuvant therapy by risk stratification (histology/grade/myometrial invasion/LVSI/molecular) deciding observation, vaginal brachytherapy, external-beam pelvic radiation or chemotherapy, Notes: FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage） Inputs: Histologic type Aggressive (G3, serous, clear-cell, carcinosarcoma, undifferentiated, etc.), Anatomic extent Distant metastasis (IVC), Molecular subtype NSMP → Result: FIGO stage Stage IVCmNSMP（FIGO 2023 stage: Stage IVCmNSMP (MMRd/NSMP do not change the stage, recorded as a subscript only; for stage III/IV the molecular subtype is recorded only), Management direction: Surgery (aim for optimal cytoreduction) + platinum chemotherapy ± radiation; advanced/recurrent may add immunotherapy (dMMR/MMRd: dostarlimab/pembrolizumab; pMMR: combined with lenvatinib), Notes: FIGO 2023 distinguishes non-aggressive (G1–2 endometrioid) from aggressive histology; complete molecular classification is encouraged (POLE sequencing + MMR IHC + p53); POLEmut de-escalates and p53abn escalates (changing the stage only for early confined disease), while MMRd/NSMP are recorded as subscripts only; for stage III/IV molecular subtype does not change the stage）